Form 4: Karen H. Vousden Reports Acquisition of Bristol-Myers Squibb Deferred Share Units

Director Karen H. Vousden reports acquisition of deferred share units in Bristol-Myers Squibb, convertible to common stock upon cessation of directorship or at a specified future date.

Summary

• Karen H. Vousden, a director of Bristol-Myers Squibb, filed a Form 4 indicating changes in beneficial ownership.
• On February 1, 2025, Vousden acquired 3,562.341 deferred share units, each convertible into one share of Bristol-Myers Squibb common stock upon settlement.
• The settlement of these units occurs when Vousden ceases to be a director or at a previously specified future date.
• The price of the deferred share units was $58.95.
• Following the reported transaction, Vousden beneficially owns 35,232.035 derivative securities, which includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, neither particularly positive nor negative. It simply reports a transaction.

Future Outlook

The deferred share units will be converted into common stock upon settlement when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

This filing is a routine disclosure related to director compensation and equity ownership, common in publicly traded companies. It provides transparency to investors regarding the alignment of director interests with shareholder value.

Stakeholder Impact

• The filing provides transparency to shareholders regarding director equity ownership.
• It assures stakeholders that directors' interests are aligned with those of the shareholders through equity-based compensation.

Key Dates

Keywords

Form 4, Beneficial Ownership, Deferred Share Units, Director, Bristol-Myers Squibb, BMY, Vousden, Karen H. Vousden